We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

    Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 Sensei CEO John Celebi (Photo: Business Wire) GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical companyRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

    Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 Sensei CEO John Celebi (Photo: Business Wire) GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical companyRead More

Signup For Update

sign up for newsletter and get the latest update